Table 2

The primary outcomes of IVC group and IVR group

IVC groupIVR groupTχ2 P value
Recurrent eyes/patient10/514/7/0.830.36
Recurrence rate16.67%23.34%///
PMA at initial treatment in recurrent infant (w)34.60±3.4735.14±1.76−0.36/0.728
PMA at second treatment in recurrent infant (w)43.31±3.8543.43±3.89−0.05/0.961
Interval between two treatment(w)8.71±6.628.29±2.560.16/0.878
  • IVC, intravitreal injection of conbercept; IVR, intravitreal injection of ranibizumab; PMA, postmenstrual age.